InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.545 -0.12 (-18.05%)+
Announcement
Release
19 Nov 2025 8:30AM
Price at Release
$0.665
Full Release
download
Summary
Cyclopharm Limited's Bell Potter Healthcare Conference Presentation highlights the company's expansion and growth strategies, particularly focusing on the U.S. market. The company aims to increase Technegas installations to 250-300 in the U.S. during the second half of CY2026. Cyclopharm is leveraging its Technegas technology, which provides high diagnostic accuracy and low radiation exposure, to extend its market beyond pulmonary embolism (PE) into chronic respiratory diseases such as COPD and asthma. The presentation outlines a strong U.S. sales force expansion and a pipeline of revenue-generating sites, with an emphasis on recurring revenue through consumable sales and annual access fees. Cyclopharm has established a significant presence in global markets, with Technegas now available in 66 countries, and aims to capitalize on AI and analytical software to further enhance its market potential.
Key Points
  • Cyclopharm Limited aims for 250-300 Technegas installations in the U.S. by second half CY2026.
  • Technegas offers high diagnostic accuracy and low radiation exposure.
  • Expansion into chronic respiratory diseases market, such as COPD and asthma.
  • Significant presence in 66 countries with plans to leverage AI and analytical software.
  • U.S. sales force expansion and strong pipeline of revenue-generating sites.
  • Focus on recurring revenue through consumable sales and annual access fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.